Nintedanib Clonmel (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—preventing downstream signalling that leads to fibroblast proliferation, new blood‑vessel formation and extracellular‑matrix deposition. This multi‑target inhibition reduces fibrotic tissue remodeling and limits tumour‑related vascular growth.

The specific dose and dosing schedule for Nintedanib Clonmel are determined by the prescribing clinician based on the patient’s condition, weight, organ function and other individual factors. No fixed regimen is provided here; the prescriber will set the appropriate regimen.

Safety data for nintedanib in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It is generally avoided in pregnant or nursing women unless the potential benefit outweighs the potential risk, and a healthcare professional should be consulted.

To request Nintedanib Clonmel, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

The primary alternative for IPF is pirfenidone, another antifibrotic agent. While both drugs aim to slow disease progression, nintedanib targets multiple tyrosine kinases, whereas pirfenidone’s mechanism involves inhibition of transforming growth factor‑β signalling. Choice between them depends on efficacy, tolerability, patient comorbidities and physician preference.

Nintedanib Clonmel should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency throughout its shelf life.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole with water and follow any specific instructions regarding timing or dose adjustments provided by their healthcare professional.

Serious adverse events include significant liver enzyme elevations, severe bleeding, cardiovascular complications such as myocardial infarction, gastrointestinal perforation, and rare cases of pulmonary embolism. Patients should be monitored regularly for these events, and therapy should be discontinued if any serious reaction occurs.

Patients with known hypersensitivity to nintedanib or any excipients, those with severe hepatic impairment, uncontrolled cardiovascular disease, active bleeding disorders, or who are pregnant or breastfeeding without a clear benefit‑risk justification should avoid using Nintedanib Clonmel.